Casdin Capital’s bluebird bio BLUE Stock Holding History
Bought
Maintained
Sold
Other funds holding BLUE
CS
AC
SCM
Casdin Capital's BLUE Position: Q1 2021 in Review
Casdin Capital sold out of bluebird bio (BLUE) in Q1 2021, closing a stake of 70,638 shares — an estimated $39.6M sold.
Casdin Capital first reported a position in BLUE in Q4 2015 and held it in 21 quarters. The position peaked at $85.1M in Q4 2019. 229 funds tracked by Wall St. Rank hold BLUE as of Q1 2021.
- Casdin Capital reported no remaining bluebird bio position as of Q1 2021 after selling out during the quarter.
- Casdin Capital sold 70,638 bluebird bio shares in Q1 2021, an estimated $39.6M.
- Casdin Capital first reported a position in bluebird bio in Q4 2015 and held it in 21 quarters.
- Casdin Capital's bluebird bio position peaked at $85.1M in Q4 2019.
- 229 funds tracked by Wall St. Rank held bluebird bio as of Q1 2021.
Based on Casdin Capital's 13F filing for Q1 2021, filed 17 May 2021.